Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial

Main Article Content

Bruce Strober
Yale University School of Medicine

Yayoi Tada
Department of Dermatology, Teikyo University School of Medicine

Ulrich Mrowietz
Psoriasis Center, Department of Dermatology, University Medical Center Schleswig-Holstein

Mark Lebwohl
Icahn School of Medicine at Mount Sinai Department of Dermatology

Peter Foley
The University of Melbourne, St. Vincent’s Hospital Melbourne

Richard G Langley
Dalhousie University

Jonathan Barker
St. John’s Institute of Dermatology, King’s College London

Maggie Wang
UCB Pharma

Veerle Vanvoorden
UCB Pharma

Balint Szilagyi
UCB Pharma

Valerie Ciaravino
UCB Pharma

Carle Paul
Toulouse University and CHU

Keywords

bimekizumab, biologic, psoriasis, BE BRIGHT, moderate to severe, clinical trial

Abstract

N/A

References

1. Yiu ZZN et al. Br J Dermatol 2020;183:294–302

2. Warren RB et al. N Engl J Med 2021;385:130–41

3. Reich K et al. Lancet 2021;397:487–98

4.Gordon KB et al. Lancet 2021;397:475–86

5. Strober B et al. Presented at EADV 2021; P1317

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.65

Article Details

How to Cite
[1]
Strober, B., Tada, Y., Mrowietz, U., Lebwohl, M., Foley, P., Langley, R.G., Barker, J., Wang, M., Vanvoorden, V., Szilagyi, B., Ciaravino, V. and Paul, C. 2022. Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s65. DOI:https://doi.org/10.25251/skin.6.supp.65.
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Poster Presentations from FC22 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>